Craig Mull, CEO of Cipher Pharmaceuticals, and Bryan Jacobs, President, delve into the company’s strategic focus on dermatology. They discuss their impressive acquisition of Natroba, reshaping their product lineup for younger audiences. Listeners learn about ongoing clinical trials for nail fungus treatments, challenges in the competitive landscape, and operational synergies post-acquisition. The pair outlines their ambitious 3-5 year vision, emphasizing innovation and market expansion in specialty pharmaceuticals. This engaging conversation reveals the future of dermatological care.
